The latest price target for Rapport Therapeutics (NASDAQ:RAPP) was reported by Jones Trading on October 18, 2024. The analyst firm set a price target for $42.00 expecting RAPP to rise to within 12 months (a possible 134.64% upside). 4 analyst firms have reported ratings in the last year.

The latest analyst rating for Rapport Therapeutics (NASDAQ:RAPP) was provided by Jones Trading, and Rapport Therapeutics initiated their buy rating.

There is no last upgrade for Rapport Therapeutics

There is no last downgrade for Rapport Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rapport Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rapport Therapeutics was filed on October 18, 2024 so you should expect the next rating to be made available sometime around October 18, 2025.

While ratings are subjective and will change, the latest Rapport Therapeutics (RAPP) rating was a initiated with a price target of $0.00 to $42.00. The current price Rapport Therapeutics (RAPP) is trading at is $17.90, which is within the analyst’s predicted range.